Madurai News

Sarcopenia Epidemiology Forecast to 2030 By Delveinsight

 Breaking News
  • No posts were found

Sarcopenia Epidemiology Forecast to 2030 By Delveinsight

July 30
11:52 2020
Sarcopenia Epidemiology Forecast to 2030 By Delveinsight

(Albany, US) DelveInsight has launched a new report on Sarcopenia Epidemiology

DelveInsight’s Sarcopenia Epidemiology Forecast to 2030 report delivers an in-depth understanding of the disease, historical and forecasted Sarcopenia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Sarcopenia is a condition which is characterized by loss of muscle mass, muscle strength and functional muscle impairment with ageing. The definition has been through various alterations. However, an enormous recent breakthrough is the inclusion of the condition in the ICD-10 classification of diseases. The physical consequences of this disease put a person at risk for falls, fractures, and hospitalization, thereby affecting the quality of life and death in extreme cases. The etiology of sarcopenia is a constellation of factors involving the aging neuromuscular machinery (motor unit number and efficiency, muscle architecture and orientation, fiber type distibution), reduced anabolic hormone levels, muscle disuse, and inflammation driven by environmental, genetic and behavioral factors

 

 

 

Request for free sample page:- https://www.delveinsight.com/sample-request/sarcopenia-epidemiology-forecast

 

Sarcopenia Epidemiology

Current definitions of sarcopenia are only newly developed and still not entirely accepted. Reported prevalence rates of sarcopenia vary significantly due to differing definitions, tools of diagnosis, and patient populations. Estimates range from 10% in individuals >65 years of age, rising to 30% in men over 80. Early recognition and intervention is the key to improved outcomes in patients with sarcopenia. Screening patients for impairment in their physical function and activities of daily living (ADLs) should be a routine part of healthcare visits for the elderly. Assessment of the effect of interventions in research and clinical practice is required to enable them to be targeted.

Sarcopenia Epidemiology Perspective by DelveInsight

The Sarcopenia epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Sarcopenia epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Sarcopenia epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Key facts of the report

  • The prevalence of sarcopenia ranges from 15% at 65 years to 50% at 80 years in humans, with normal aging associated with a 1–2% muscle loss beyond the age of 50 years.
  • As per Delveinsight estimates, the total prevalent population of sarcopenia in the 7MM was found to be 33,321,576 in 2017.
  • According to Delveinsight, males are affected more as compared to females in case of sarcopenia
  • Japan accounted for 2,890,096 cases sarcopenia in 2017, which accounted for approximately 8.67% of the total 7MM prevalent cases of sarcopenia.

 

Sarcopenia Report Scope

  • The Sarcopenia report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Sarcopenia Epidemiology Report and Model provide an overview of the risk factors and global trends of Sarcopenia in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Sarcopenia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Sarcopenia
  • The report provides the segmentation of the Sarcopenia epidemiology

 

Request for free sample page:- https://www.delveinsight.com/sample-request/sarcopenia-epidemiology-forecast

 

Table of content

1. Key Insights 

2. Executive Summary of Sarcopenia

3. Sarcopenia: Disease Background and Overview

4. Patient Journey

5. Epidemiology and Patient Population

6. Treatment Algorithm, Current Treatment, and Medical Practices

7. KOL Views

8. Unmet Needs

9.  Appendix

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

 

Why should you buy this report?

  • The Sarcopenia Epidemiology report will allow the user to –
  • Develop business strategies by understanding the trends shaping and driving the global Sarcopenia market
  • Quantify patient populations in the global Sarcopenia market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Sarcopenia therapeutics in each of the markets covered
  • Understand the magnitude of Sarcopenia population by its epidemiology
  • The Sarcopenia Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

 

Related Reports

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/